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 Abstract
 MicroRNAs are emerging as a hot topic in research, and rightfully so. They show great prom-
ise as targets of treatment and as markers for common human diseases, such as cancer and 
metabolic diseases. In this review, we address some of the basic questions regarding micro-
RNA function in human disease and the clinical significance of microRNAs. Specifically, micro-
RNAs in epigenetics, cancer, and metabolic diseases are discussed, with examples taken from 
cholangiocarcinoma and nonalcoholic fatty liver disease.  © 2013 S. Karger AG, Basel
 Introduction
 MicroRNAs are small, endogenously expressed, single-stranded, noncoding RNAs about 
19–24 nucleotides in length  [1] . Found throughout the human genome, microRNAs work to 
fine-tune gene expression  [2, 3] . This leads to the following question: are microRNAs 
epigenetic? Many factors need to be carefully considered before answering this question. 
What we know for certain is that microRNAs, or more specifically their aberrant expression, 
are linked to all human cancers. The current review specifically looks at the aberrant 
expression of a multitude of microRNAs implicated in cholangiocarcinoma, tabulating 
microRNAs known to be dysregulated in malignant cells and tumors, as compared to normal 
cells and tissue. Additionally, microRNAs play a major regulatory role in metabolic diseases, 
such as nonalcoholic fatty liver disease. Much like in cancer, an aberrant expression of 
microRNAs has been reported in patients with metabolic disease. Since microRNAs can be 
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easily found in tissue and biological fluids such as serum  [4] , cerebrospinal fluid  [5] , aqueous 
humor  [6] , milk  [7] , bile  [8] , peritoneal fluid  [7] , ovarian follicular fluid  [9] , and urine  [10] , the 
measurement of microRNA expression levels can be used to detect diseases. In addition to 
disease detection, successful treatment can result in a return to normal levels of microRNAs, 
suggesting a role in disease monitoring and prognosis. Unfortunately, we cannot provide a 
comprehensive review of the state of microRNA research, due in no small part to the rapid 
proliferation of microRNA studies; we hope to provide a few illustrative examples because 
microRNAs will have an important role in both the diagnosis and treatment of human diseases.
 MicroRNA Function
 MicroRNAs are expressed from a dedicated gene (termed intergenic with reference to 
protein-coding genes) or are processed from the RNA of a host gene (whereby both the mRNA 
and microRNA are products of the same primary transcript). The mature microRNA sequence 
can be derived from either introns or exons. MicroRNAs can be grouped into larger microRNA 
families which share conserved sequences. Within the genome, microRNAs are found clus-
tered together or single, and clusters can contain related family members or disparate 
microRNAs. Once expressed, microRNAs are incorporated into the RNA-induced silencing 
complex and direct repression of a target mRNA by base complementarity within a 6- to 
8-nucleotide sequence, the ‘seed’ sequence, of the microRNA  [11, 12] . This leads to either 
degradation or repression of the target mRNA, impacting proliferation, apoptosis, and differ-
entiation of cells. MicroRNAs act on several oncogenes or tumor suppressors, contributing to 
cancer formation and progression. Importantly, aberrant expression of microRNAs has been 
linked to all human cancers. In addition to cancer biology, microRNAs target a high proportion 
of cellular mRNAs (estimated as high as 60% of genes) and can impact normal physiology and 
nonmalignant disease. On the clinical level, microRNAs are surfacing as a novel diagnostic 
tool for the early detection, classification, and perhaps treatment of human disease.
 MicroRNAs and Epigenetics
 Should gene regulation by microRNAs always be considered an epigenetic process? 
There is controversy concerning the exact definition of epigenetics and whether it is necessary 
for an epigenetic effect to be heritable through either a meiotic or mitotic cell division  [13, 
14] . Indeed, there are arguably cases where the same molecular change in one circumstance 
is heritable and in another is transient. Fittingly, there is also difficulty in determining if the 
effects of microRNAs to fine-tune gene expression should be considered epigenetic. If the 
heritability standard is enforced, then microRNAs would generally be considered regulatory. 
However, note that in the absence of microRNAs, the development of the zebrafish is impaired 
(e.g., gastrulation, brain formation, somitogenesis, and heart development), but injection of 
miR-430 into the single-cell fertilized embryo resulted in phenotypic rescue of these later-
stage processes. Further, the model embryos had to be deficient in microRNAs  and derived 
from an egg lacking microRNAs (maternal-zygotic deletion), because the maternal contri-
bution was sufficient to allow development. The rescue of later-stage developmental processes 
by either maternally derived or injected miR-430 is consistent with this microRNA acting in 
daughter cells after several rounds of division, for example a heritable effect  [15] . This does 
not indicate that miR-430 expression was self-reinforcing, but only that some microRNAs are 
stable enough to maintain a functional concentration in a daughter cell even after numerous 
cell divisions. To complicate matters, microRNAs are regulated by classic imprinting [reviewed 
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in  16–18 ] and can target proteins mechanistically involved in epigenetic DNA methylation, 
for example DNMT3 and DNMT1  [19, 20] and methyl CpG binding protein 2  [21] . Thus, it may 
be better to ask whether a  specific microRNA is acting in an epigenetic manner rather than 
broadly trying to classify all microRNA effects as epigenetic.
 MicroRNAs in Cancer
 Early in the study of microRNAs in human disease, it became clear that microRNAs were 
involved in cancer. For instance, a minimally deleted region of chromosome 13 in chronic 
lymphocytic leukemia contained the related microRNAs, miR-15a and miR-16-1, and these 
microRNAs were lost or decreased in cancerous cells  [22] . Separately, the analysis of small 
RNAs cloned and sequenced from colorectal adenocarcinoma tissues revealed decreased 
levels of miR-143 and miR-145, with levels of both reduced versus nontumor colonic tissues 
 [23] . Since these early studies, there has been a marked expansion in microRNA research. 
Altered microRNA expression is now well recognized in human malignancies, including 
examples where microRNAs are expressed at abnormally high levels in tumor cells or at 
significantly reduced levels. Because there is far more information on microRNAs in cancer 
than can be covered in a single short review, we have chosen to discuss microRNAs in the 
biliary tract cancer cholangiocarcinoma, an area of active research in our lab, as an illustrative 
example.
 MicroRNAs in Cholangiocarcinoma
 Cholangiocarcinoma is a relatively rare but highly malignant cancer of the biliary tree 
that shares a number of features with other cancers, including the risk factors for chronic 
inflammation and injury  [24] . Aberrant microRNA expression has been implicated in cholan-
giocarcinoma progression, though our understanding is still incomplete.  Table 1 lists 47 
microRNAs whose expression is increased in cholangiocarcinoma. It is organized to group 
microRNAs from the same family that share sequence similarity, and presumably function, 
with other family members. Not all members of the family are included in  table 1 , but only 
those with altered levels in disease. The 47 increased microRNAs represent 34 microRNA 
families. On the other hand, 53 microRNAs are decreased in cholangiocarcinoma ( table 2 ) 
that belong to 42 microRNA families. There is some overlap, with 5 microRNAs, miR-22-3p, 
miR-122-5p, miR-200c-3p, miR-221-3p, and miR-424-5p, having been measured at increased 
and decreased levels in different studies. Whether this reflects differences in disease etiology, 
stage, or behavior is not yet known. Note that the expression changes – either up or down – 
have been linked with a functional target in the minority of cases. Studies in other tumor types 
as well as future studies in cholangiocarcinoma will help determine the functional role of each 
of the altered microRNAs.
 MicroRNAs in Metabolic Disease
 Metabolic syndrome is defined as three or more of the following: abdominal obesity, 
hypertriglyceridemia, low HDL cholesterol, hypertension, and elevated blood glucose. Meta-
bolic syndrome has an estimated prevalence of up to 34% of all adults in the USA  [25] . Diseases 
associated with metabolic disease, including obesity, coronary artery disease, type 2 diabetes, 
nonalcoholic fatty liver disease, and polycystic ovarian syndrome, each have been reported 
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to have altered microRNA expression and function  [9, 26–36] . MicroRNAs are involved in a 
number of metabolic processes, such as maintenance of cellular glucose, cholesterol, triglyc-
eride, and fatty acid metabolism  [37] .
 A pathologic contribution of microRNAs to metabolic syndrome seems likely, including a 
role in inflammation. For example, decreased expression of miR-132 and miR-155 in adipose 
tissue is associated with increased expression of the proinflammatory cytokine IL-6 in obese 
 miR family  miR members  Targets /functions  Ref. No. 
 8  141-3p/200b-3p/
200c-3p/429 
 apoptosis (200b-3p)  57, 63, 74 
 10  10a-5p  74 
 15  15a-5p/15b-5p  61 
 17  17-5p/17-3p/
 20a-5p/20b-5p/
 93-5p/106a-5p/
106b-5p 
 61, 62, 64,
74 
 19  19a-3p  61, 62 
 21  21-5p  PTEN, PDCD4, TIMP3, 
 invasion, metastasis, 
tumor growth, 
apoptosis 
 57, 61, 62,
65, 66,
71  –  74 
 22  22-3p    74 
 24  24-3p    74 
 25  25-3p  DR4, apoptosis  61, 62, 64 
 26  26a-5p  GSK-3β, proliferation  68 
 27  27a-3p  74 
 28  151a-3p  74 
 29  29a-3p/29b-3p  74 
 30  30b-5p/30e-5p  74 
 96  96-5p  74 
 103  103a-3p/107  61, 74 
 122  122-5p  74 
 130  130b-3p  61 
 135  135b-5p  74 
 142  142-3p  61 
 181  181a-5p  74 
 192  192-5p  63 
 193  193a-3p  61 
 203  203a  74 
 221  221-3p  74 
 223  223-3p  61, 72 
 224  224-5p  61 
 322  424-5p  74 
 324  324-5p  61 
 331  331-3p  61 
 340  340-5p  74 
 374  374a-5p  61 
 663  663b  74 
 MicroRNAs found to be increased in human cholangiocarcinoma 
cells or tissues are listed by family, with the particular altered microRNA 
listed in the ‘members’ column. When studied, the function and/or 
target protein(s) are included. 
 Table 1.  Upregulated microRNAs 
in cholangiocarcinoma
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 miR family  miR members  Targets/func tions  Ref. No. 
 1  1    74 
 let-7  let-7a-5p/let-7b-  NF2 (let-7a-5p),  58, 61, 
 5p/let7c/98-5p  apoptosis  74 
 8  200c-3p  NCAM1, epithelial-  61, 70, 
 mesenchymal  72 
 transition 
 29  29b-3p  Mcl-1, apoptosis  59 
 22  22-3p  63 
 31  31-5p  72 
 99  99a-5p/100-5p  74 
 122  122-5p  72 
 124  124-3p  SMYD3, migration and  69 
 invasion 
 125  125a-5p/125b-5p  63, 74 
 126  126-3p  74 
 127  127-3p  63, 74 
 139  139-3p  74 
 144  144-3p  74 
 145  145-5p  61, 72,
 74 
 146  146a-5p  72 
 148  148a-3p/152  DNMT1, proliferation  20 
 154  494  PTTG1, TOP2A, cell  62, 67 
 cycle progression 
 184  184  61 
 185  185-5p  61 
 188  188-5p  62 
 197  197-3p  61 
 191  191-3p  62 
 198  198  61, 62 
 199  199a-5p  63 
 204  204-5p  61 
 214  214-3p  Twist, epithelial-  61, 63, 
 mesenchymal transition  66 
 221  221-3p/222-3p 61, 72
 290  371a-3p 61
 302  302b-3p/302d-3p 61
 320  320a 61
 322  424-5p 63
 328  328 61
 337  337-3p 61, 74
 338  338-3p 61
 368  376a-3p 63, 74
 370  370  MAP3K8, proliferation  60, 62 
 373  373-3p  61 
 451  451a  74 
 506  512-3p/513a-5p  62 
 515  517c-3p/519a-  62, 74 
 3p/520e 
 630  630  74 
 662  662  62 
 MicroRNAs that were decreased in cholangiocarcinoma cells or 
tissues are grouped by family, and individually altered microRNAs are 
listed as miR members. If known, the relevant target proteins or func-
tions in cholangiocarcinoma are included. 
 Table 2.  Downregulated 
microRNAs in
cholangiocarcinoma
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f N
eb
ra
sk
a-
Li
nc
ol
n 
Li
br
ar
ie
s
12
9.
93
.1
6.
87
 - 
1/
19
/2
01
7 
11
:5
4:
01
 P
M
111Med Epigenet 2013;1:106–115
 DOI: 10.1159/000356447 
 Natarajan et al.: MicroRNA Function in Human Diseases 
www.karger.com/mee
© 2013 S. Karger AG, Basel
individuals  [38] ; studies in patients with nonalcoholic fatty liver disease have revealed a 
similar increase in hepatic and circulating levels of IL-6  [39, 40] . For additional information 
regarding altered expression of microRNAs in adipocyte differentiation, inflammation, adipo-
genesis, and insulin signaling in obese individuals, we refer the reader to excellent recent 
reviews  [38, 41] . Here, we will further discuss microRNA signaling in nonalcoholic fatty liver 
disease.
 Altered MicroRNA Levels in Nonalcoholic Fatty Liver Disease
 Nonalcoholic fatty liver disease is a spectrum of liver disease including simple steatosis, 
nonalcoholic steatohepatitis (NASH), advanced hepatic fibrosis, liver cirrhosis, and hepato-
cellular carcinoma  [42] . Aberrant expression of various microRNAs has been reported in 
patients with NASH  [26, 43] . NASH patients, for example, had elevated levels of miR-34a and 
miR-146 and decreased levels of miR-122 in the liver  [26] , and increasing miR-34a expression 
in the liver was found to correlate with increasing severity of NASH  [44, 45] . Free fatty acid-
 Fig. 1. MicroRNAs are released from cells. MicroRNAs have been detected in many extracellular fluids, and 
are potentially released by regulated processes such as exosome-mediated release or as part of lipid particles 
(not shown). Alternatively, injury (either necrotic or apoptotic) can result in the release of intracellular mi-
croRNAs into the extracellular compartment. Note that endogenous microRNAs detected in biological fluids 
are consistently more stable than exogenous microRNAs spiked into the same sample. This is consistent with 
protection of endogenous microRNAs in ribonucleoprotein complexes, in membrane-bound vesicles, or in 
another stabilizing complex. RISC = RNA-induced silencing complex.
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induced lipotoxicity is due, in part, to an increase in miR-34a expression in hepatocytes 
resulting in repression of the antiapoptotic protein, Sirt1 (a protein deacetylase). Decreased 
Sirt1 expression caused by miR-34a results in an increase in acetylation of p53 and activates 
the expression of p53 targets such as PUMA, a proapoptotic BH3-containing protein, promoting 
the induction of hepatocyte lipoapoptosis  [44] . Indeed, PUMA dysregulation appears to be 
important in nonalcoholic fatty liver disease, as levels of PUMA mRNA and protein were 
elevated in patients with NASH compared with patients with simple steatosis and control 
population  [46] . Separately, PUMA expression in nonalcoholic fatty liver disease was 
controlled by miR-296-5p, which was downregulated in patients with NASH  [47] .
 MicroRNA Measurement in Disease
 MicroRNAs can be detected in diseased tissue as well as in biological fluids. Some of the 
mechanisms of microRNA release from the cell of origin are diagrammed in  figure 1  [48–52] , 
and microRNAs can communicate between cells  [53] . Thus, the measurement of altered 
microRNAs can be performed from tissue biopsies or from relevant biological fluids. In the 
latter case, detection of microRNAs in biological fluids still leaves a question as to their cell of 
origin  [54] . If the diseased tissue is releasing more microRNAs, it may be a reflection of cellular 
injury or increased synthesis and export. If another cellular source is responsible, the 
increased extracellular microRNA may reflect injury to a secondary tissue or recruitment of 
an inflammatory cell, for instance. This ambiguity should be considered when altered 
microRNAs in fluids are observed, but also may allow for the detection of related pathologic 
processes.
 In addition to a correlation between microRNA expression and disease, successful 
treatment can result in a return to normal microRNA levels. In the case of obesity, for example, 
the circulating levels of miR-140-5p and miR-142-3p progressively increased in nonobese 
(BMI <30) to obese (BMI 30–40) to morbidly obese (BMI >40) patients. After bariatric surgery, 
the circulating levels of miR-140-5p and miR-142-3p were markedly decreased  [55] . Of 
potential importance, miR-140-5p and miR-142-3p are both highly expressed in blood 
neutrophils  [56] . It is not clear whether increased circulating miR-140-5p and miR-142-3p in 
obese individuals originated from blood cells, such as neutrophils (potentially reflecting the 
inflammatory component of obesity), or from a tissue more traditionally associated with 
obesity.
 Conclusions
 MicroRNAs, whether considered epigenetic or regulatory, play a major role in human 
diseases. Aberrant expression of microRNAs has been reported in all cancers. Altered also in 
metabolic diseases, it is clear that microRNAs and their significance in clinical medicine 
should be looked into more closely. The ability to detect microRNAs in tissue and biological 
fluids makes them highly useful for early diagnosis of disease. Perhaps even more significant 
would be the ability to use microRNAs to treat human disease through the return of normal 
microRNA levels. It is evident that microRNAs will play a major role in the future diagnosis 
and treatment of human disease.
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